Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phen-an-ka-min is a combination oral tablet developed and manufactured by Sinopharm Xingsha Pharmaceuticals, primarily used for the symptomatic treatment of the common cold and influenza. The formulation contains paracetamol (acetaminophen), chlorpheniramine maleate, and caffeine. Paracetamol provides analgesic and antipyretic effects by inhibiting cyclooxygenase enzymes and reducing prostaglandin synthesis in the central nervous system. Chlorpheniramine is a first-generation antihistamine that competes with histamine for H1 receptor sites, effectively relieving symptoms such as rhinorrhea, sneezing, and watery eyes. Caffeine is included as a central nervous system stimulant to alleviate the drowsiness often caused by chlorpheniramine and to potentially enhance the analgesic efficacy of paracetamol. This product is an established generic medication in the Chinese market.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Phen-an-ka-min.